Want to see TARS full AI Analyst Report?
Tarsus Pharmaceuticals (TARS) Stock Forecast & Price Target
TARS Analyst Ratings
TARS Stock 12 Month Forecast
Average Price Target
$100.13▲(33.77% Upside)Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Graig Suvannavejh | Mizuho Securities | $100→$94 | buy | 25.58%Upside | Reiterated | 10/29/26 | ||
| Jason Gerberry | Bank of America Securities | $84 | buy | 12.22%Upside | Reiterated | 10/12/26 | ||
| Jenna Davidner | Barclays | $110 | buy | 46.96%Upside | Reiterated | 10/09/26 | ||
| Mazahir Alimohamed | Oppenheimer | $100 | buy | 33.60%Upside | Reiterated | 10/02/26 | ||
| Andrea Newkirk | Goldman Sachs | $116 | buy | 54.98%Upside | Initiated | 09/24/26 | ||
| Dennis Ding | Jefferies | $105 | buy | 40.28%Upside | Reiterated | 09/08/26 | ||
| Lachlan Hanbury Brown | William Blair | ― | buy | ― | Reiterated | 08/12/26 | ||
| Francois Brisebois | LifeSci Capital | $104 | buy | 38.94%Upside | Assigned | 08/08/26 | ||
| Matthew Caufield | H.C. Wainwright | $88 | buy | 17.57%Upside | Reiterated | 08/07/26 | ||
| Eddie Hickman | Guggenheim | $90→$89 | buy | 18.90%Upside | Reiterated | 07/21/26 | ||
| Andreas Argyrides | Chardan Capital | $105→$98 | buy | 30.93%Upside | Reiterated | 04/24/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Graig Suvannavejh | 10/29/26 | $100→$94 | buy | 25.58%Upside | Reiterated | Mizuho Securities | ||
| Jason Gerberry | 10/12/26 | $84 | buy | 12.22%Upside | Reiterated | Bank of America Securities | ||
| Jenna Davidner | 10/09/26 | $110 | buy | 46.96%Upside | Reiterated | Barclays | ||
| Mazahir Alimohamed | 10/02/26 | $100 | buy | 33.60%Upside | Reiterated | Oppenheimer | ||
| Andrea Newkirk | 09/24/26 | $116 | buy | 54.98%Upside | Initiated | Goldman Sachs | ||
| Dennis Ding | 09/08/26 | $105 | buy | 40.28%Upside | Reiterated | Jefferies | ||
| Lachlan Hanbury Brown | 08/12/26 | ― | buy | ― | Reiterated | William Blair | ||
| Francois Brisebois | 08/08/26 | $104 | buy | 38.94%Upside | Assigned | LifeSci Capital | ||
| Matthew Caufield | 08/07/26 | $88 | buy | 17.57%Upside | Reiterated | H.C. Wainwright | ||
| Eddie Hickman | 07/21/26 | $90→$89 | buy | 18.90%Upside | Reiterated | Guggenheim | ||
| Andreas Argyrides | 04/24/26 | $105→$98 | buy | 30.93%Upside | Reiterated | Chardan Capital |
Best Analysts Covering Tarsus Pharmaceuticals
Copying Lachlan Hanbury Brown's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +14.17% per trade.
Copying Eddie Hickman's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +51.60% per trade.
Copying Francois Brisebois's trades and holding each position for 2 Years would result in 95.65% of your transactions generating a profit, with an average return of +114.35% per trade.
TARS Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 14 | 12 | 13 | 4 |
| Buy | 10 | 12 | 10 | 11 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 16 | 26 | 22 | 24 | 13 |
In the current month, TARS has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TARS average Analyst price target in the past 3 months is 100.13.
TARS Financial Forecast
TARS Earnings Forecast
Next quarter’s earnings estimate for TARS is -$1.46 with a range of -$2.01 to -$0.44. The previous quarter’s EPS was -$0.43. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
TARS Sales Forecast
Next quarter’s sales forecast for TARS is $187.83M with a range of $179.63M to $196.08M. The previous quarter’s sales results were $173.91M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.